Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Trial Profile

Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isoniazid (Primary) ; Rifapentine (Primary)
  • Indications Tuberculosis
  • Focus Therapeutic Use
  • Acronyms BRIEF-TB
  • Most Recent Events

    • 10 Mar 2021 Results assessing adverse pregnancy outcomes among women exposed to IPT in a secondary analysis, presented at the 28th Conference on Retroviruses and Opportunistic Infections
    • 26 Nov 2020 Results assessing effect of daily 1HP on nevirapine PK in the first 90 participants who enrolled in BRIEF-TB published in the Journal of Antimicrobial Chemotherapy
    • 11 Mar 2020 Results assessing geographic and individual risk factors for Tuberculosis or death in the Brief-Tb Trial, presented at the 27th Conference on Retroviruses and Opportunistic Infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top